What is Melaseq™?

Melaseq is an innovative genomic test developed in Australia to enhance the accuracy of melanoma diagnosis. By detecting specific microRNA biomarkers in blood and tissue samples, Melaseq offers a more precise assessment when used alongside clinical expertise and standard diagnostic methods.

Scroll down to down for a step-by-step guide.

Step 1: Understanding Your Melanoma Risk

Over one million Australians are at risk of developing invasive melanoma. However, early detection leads to a 90%+ survival rate.

To estimate your personal risk, use an online melanoma risk calculator specific to your region and speak with your doctor about your screening options.

Step 2: A Simple Blood Test for Early Detection

Melanoma can develop in areas that are hard to detect, including regions not exposed to the sun.

As melanoma progresses, it releases unique microRNA biomarkers into the bloodstream.

Melaseq Liquid Biopsy detects these biomarkers through a simple blood test, offering a non-invasive option for early melanoma detection.

Step 3: Cutting-Edge Genomic Analysis

Melaseq uses state-of-the-art genomic technology to analyse specific microRNA signals linked to invasive melanoma.

A personalised genomic score is generated, along with a confidence estimate, to help determine whether further diagnostic evaluation is necessary.

Step 4: Actionable Results

Class A: A low Melaseq score indicates a minimal risk of invasive melanoma.

0
10

Next Step: Continue routine skin checks

Class B: A high Melaseq score suggests a greater likelihood of invasive melanoma.

0
10

Next Step: Book a skin check with a specialist

Step 5: Melaseq on Biopsy Samples

If a skin biopsy is performed during your examination, the same tissue sample examined by your pathologist can also be analysed with Melaseq.

Melaseq Solid Tissue analyses skin tissue samples to identify microRNA biomarkers that mirror those found in blood, providing complementary molecular insights into the biopsied lesion.

Step 6: Ongoing Monitoring & Peace of Mind

Melaseq results are provided to your doctor to support diagnostic decisions and help guide future care.

If no concerns are found, your doctor may recommend periodic Melaseq testing along with routine skin checks to support your ongoing skin health.

Find Out Where to Access Melaseq

Select your region to learn more about availability.

Melaseq is a genomic test performed on either solid tissue or blood that evaluates the probability of invasive cutaneous melanoma (Stage I–IV). It generates a calibrated diagnostic score ranging from 0.1 to 10, derived from microRNA expression profiling. Results are reported as Class A (low probability), Class B (high probability), or Borderline, based on defined score thresholds and confidence intervals.

This test is designed to distinguish invasive melanoma from benign naevi, melanoma in situ, non-melanoma skin cancers, and normal skin. It is not intended to determine melanoma subtype or stage and should be used in conjunction with clinical judgment. Results do not replace histopathological confirmation.

Analytical validation demonstrates a sensitivity of 97% and specificity of 98% for plasma samples, and a sensitivity of 89% and specificity of 94% for FFPE tissue samples, when compared to clinical diagnoses. To assess classification confidence, the test performs approximately 500 internal simulations using bootstrap resampling. These are used to estimate the 95% confidence interval and classification stability. Each sample undergoes over 2 million computational operations to ensure a reproducible result.

Melaseq is intended for use by healthcare professionals. False positives and false negatives may occur. Additional information, including methodology and clinical evidence, is available at www.melaseq.com.